| 215 | For the treatment of emesis in cancer patients receiving highly emetogenic chemotherapy. |
| | LU Authorization Period: 1 year |
| 216 | For patients receiving intravenous chemotherapy or radiation therapy who have not experienced adequate control with other available anti-emetics. |
| | LU Authorization Period: 1 year |
| 217 | For patients receiving intravenous chemotherapy or radiation therapy who experience intolerable side effects with other anti-emetics. |
| | LU Authorization Period: 1 year |
| 218 | For the treatment of emesis in patients receiving radiation therapy which consists of single fraction treatment to the abdominal cavity, hemi-body irradiation and total body irradiation. |
| | NOTE: The therapeutic value of Ondansetron Hydrochloride more than 24 hours after the last dose of chemotherapy is unproven. |
| | LU Authorization Period: 1 year |
| 454 | For the treatment of emesis in cancer patients receiving moderately emetogenic chemotherapy (MEC) regimens. |
| | LU Authorization Period: 1 year |
